NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Company to hold conference call at 1:30 pm Pacific today
View HTML
Toggle Summary Immune Design to Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at the American Association for Cancer Research (AACR) Annual Meeting 2017
— Preclinical Data Demonstrates Tumor Eradication with "Prime-Pull" Immunotherapy Approach Combining a ZVex ® vector and G100 — — ZVex Causes Potent Activation of Dendritic Cells — SEATTLE and SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary Immune Design to Report Fourth Quarter and Year End 2016 Financial Results and Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, March 01, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth quarter and year end 2016 financial results after the close of U.S.
View HTML
Toggle Summary Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational
View HTML
Toggle Summary Immune Design to Present at Upcoming Investor Conferences
SEATTLE and SOUTH SAN FRANCISCO, Calif., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at two upcoming investor
View HTML
Toggle Summary Immune Design Provides Update from Two Discovery Platforms: DC-tropic ZVex Delivering Multiple Tumor Antigens (Conserved and Neo-Antigens) and G100 For Intratumoral Immunotherapy
SEATTLE and SOUTH SAN FRANCISCO, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Immune Design, a clinical-stage immunotherapy company focused on oncology, today announced new data that highlight the broad product reach potential of both its Specific Antigen and Endogenous Antigen/Intratumoral
View HTML
Toggle Summary New Immune Design Data Highlights Expanded Product Potential of ZVex® Platform at the 2016 SITC Annual Meeting
Introduces multiple-genome expression and new prime-boost approaches
View HTML
Toggle Summary Immune Design Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Company conference call at 1:30 p.m. PT today
View HTML
Toggle Summary Immune Design to Report Third Quarter 2016 Financial Results & Present at Upcoming Investor Conference
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report third quarter 2016 financial results after the close of U.S. financial markets on Wednesday, Nov.
View HTML
Toggle Summary Immune Design Appoints Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical Officer
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Sergey Yurasov, M.D., Ph.D. as Senior Vice President of Clinical Development and Chief Medical
View HTML